Table 1.
Patient and donor characteristics.
| Variable | Value | |
| Patients, N | 1470 | |
| Interval between diagnosis to HCTa in months, median (95% CI) | 5.7 (0-268) | |
| Recipient sex, n (%) | ||
|
|
Male | 833 (56.7) |
|
|
Female | 637 (43.3) |
| Donor sex, n (%) | ||
|
|
Male | 977 (66.5) |
|
|
Female | 493 (33.5) |
| Recipient age in years, median (range) | 41 (15-75) | |
| Donor age in years, median (range) | 34 (0-70) | |
| Donor-recipient sex, n (%) | ||
|
|
Male to male | 551 (37.5) |
|
|
Female to male | 280 (19) |
|
|
Male to female | 424 (28.8) |
|
|
Female to female | 213 (14.5) |
| Recipient disease, n (%) | ||
|
|
AMLb | 783 (66.9) |
|
|
MDSc | 188 (16.1) |
|
|
ALLd | 306 (26.2) |
|
|
Lymphoma | 56 (4.8) |
|
|
MMe | 13 (1.1) |
|
|
CMLf | 92 (7.9) |
|
|
MPNg | 16 (1.4) |
|
|
MDS-MPN | 16 (1.4) |
| HCT-CIh score, median (range) | 3 (0-8) | |
| Disease risk, n (%) | ||
|
|
Standard riski | 830 (56.5) |
|
|
High risk | 640 (43.5) |
| Donor type, n (%) | ||
|
|
Matched sibling | 591 (40.2) |
|
|
Unrelated | 387 (26.4) |
|
|
Haploidentical familial | 491 (33.4) |
|
|
Cord blood | 1 (0.1) |
| Graft source, n (%) | ||
|
|
Bone marrow | 472 (32.1) |
|
|
Peripheral blood | 997 (67.8) |
|
|
Cord blood | 1 (0.1) |
| Conditioning intensity, n (%) | ||
|
|
Myeloablative | 536 (36.5) |
|
|
Reduced intensity | 934 (63.5) |
| Treated with antithymocyte globulin to prevent GVHDj, n (%) | 903 (61.4) | |
aHCT: hematopoietic cell transplantation.
bAML: acute myeloid leukemia.
cMDS: myelodysplastic syndrome.
dALL: acute lymphoblastic leukemia.
eMM: multiple myeloma.
fCML: chronic myeloid leukemia.
gMPN: myeloproliferative neoplasm.
hHCT-CI: hematopoietic cell transplantation–specific comorbidity index.
iThe standard-risk group is defined as follows: patients with acute leukemia in the first remission (except by salvage chemotherapy), CML in the chronic phase, drug-sensitive lymphoma/MM, or MDS with bone marrow blasts ≤5% at HCT.
jGVHD: graft-versus-host disease.